Announcement Details

View all announcements

Grant of Options

Hemogenyx Pharmaceuticals plc

(“Hemogenyx Pharmaceuticals” or the “Company”)

 

Grant of Options

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, announces that the Board of Directors has agreed to grant options over a total of 6,200,626 ordinary shares of 1p each in the capital of the Company (“Share Options”) to certain PDMRs and a member of the Scientific Advisory Board of the Company.

The details of the Share Options granted are set out below:

Name Position Number of Share Options Granted Exercise Price (pence) Vesting Date Expiry Date
Peter Redmond Non-Executive Director 2,200,000 7 Vesting in quarterly tranches over the 12 months from 13 July 2020 12 July 2025
Andrew Wright Financial Controller (PDMR) 2,200,000 7 12 July 2025
Dr Alexander Tarakhovsky Scientific Adviser 1,800,626 3.5 Immediate 3 October 2022

 

Following the grant of the Share Options, in aggregate there will be 36,753,702 ordinary shares of 1p each of the Company under option to directors, employees and members of the Scientific Advisory Board of the Company, representing 8.48% of the issued ordinary share capital of the Company.

 

Enquiries:

Hemogenyx Pharmaceuticals plc hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Capital Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities (“PDMR”) and persons closely associated with them (“PCA”):

1. Details of PDMR/person closely associated with them
a) Name 1.     Peter Redmond

2.     Andrew Wright

b) Position/status 1.     Non-Executive Director

2.     Financial Controller (PDMR, non-board)

c) Initial notification/
amendment
Initial notification
2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc
Identification code GB00BYX3WZ24
b) Nature of the transaction Grant of options
c) Price(s) and volume(s)
Price(s) Volume(s)
1.     £0.07

2.     £0.07

1.     2,200,000

2.     2,200,000

 

 

d) Aggregated information

–     Aggregated volume

–     Price

Price(s) Volume(s)
N/A – variable 4,400,000
e) Date of the transaction 13/07/2020
f) Place of the transaction Outside of a trading venue

 

View all announcements